Literature DB >> 9928244

The putative 5-ht6 receptor: localization and function.

A J Sleight1, F G Boess, M Bös, A Bourson.   

Abstract

Until recently, the majority of actions of the neurotransmitter 5-hydroxytryptamine (5-HT) were generally believed to be mediated by members of the 5-HT1, 5-HT2, 5-HT3 and 5-HT4 receptor families. The application of molecular cloning techniques has revealed the existence of gene products encoding several novel, putative 5-HT receptors for which little or no prior pharmacological or functional data presently exist. The present challenge to pharmacologists is to determine the physiological relevance of these gene products, establish whether or not they function as endogenous receptors, find selective agents and determine potential therapeutic uses of these compounds. Here we review work detailing the cloning and characterization of the recombinant 5-ht6 receptor, its distribution and evidence for functional responses mediated by naturally occurring 5-ht6 receptors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9928244     DOI: 10.1111/j.1749-6632.1998.tb10178.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  6 in total

1.  5-HT(1B) but not 5-HT(6) or 5-HT(7) receptors mediate depression of spinal nociceptive reflexes in vitro.

Authors:  G Hedo; J A Lopez-Garcia
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

Review 2.  Migraine signaling pathways: amino acid metabolites that regulate migraine and predispose migraineurs to headache.

Authors:  Roger Gregory Biringer
Journal:  Mol Cell Biochem       Date:  2022-04-28       Impact factor: 3.842

3.  Pyrano[2,3,4-cd]indole as a Scaffold for Selective Nonbasic 5-HT6R Ligands.

Authors:  Jakub Staroń; Stefan Mordalski; Dawid Warszycki; Grzegorz Satała; Adam Hogendorf; Andrzej J Bojarski
Journal:  ACS Med Chem Lett       Date:  2017-03-27       Impact factor: 4.345

Review 4.  Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders.

Authors:  Bryan L Roth; S Mohammad Hanizavareh; Andrew E Blum
Journal:  Psychopharmacology (Berl)       Date:  2003-12-02       Impact factor: 4.530

5.  The Comparative Peripheral Anticholinergic-Like Adverse Event Profiles of Olanzapine and Risperidone.

Authors:  John S. Kennedy; Frank P. Bymaster; Bruce R. Basson; Julie A. Gilmore; Pierre V. Tran
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2000-08

6.  Assessing the neuronal serotonergic target-based antidepressant stratagem: impact of in vivo interaction studies and knockout models.

Authors:  R Rajkumar; R Mahesh
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.